Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abhijeet D. Joshi"'
Autor:
Abhijeet D. Joshi, Akash A Khobragade, Monisha S. Chavan, Saket S. Gaidhane, H V Likith, Akshay A. Chaware
Publikováno v:
International Journal of Basic & Clinical Pharmacology. 10:675
Background: Adverse drug reactions (ADR) are the known dangers of any medicinal therapy. They are not only responsible for increasing the mortality and morbidity but also for multiplying the health care expenditure. It is important to monitor the adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d9cb3bb1cdf01f7ad6975898e3cc454
https://doi.org/10.18203/2319-2003.ijbcp20212077
https://doi.org/10.18203/2319-2003.ijbcp20212077
Autor:
Abhijeet D. Joshi, Amitrajit A. Pal
Publikováno v:
International Journal of Basic & Clinical Pharmacology. 9:1289
Serpiginous choroiditis is a rare recurrent eye disorder which is characterized by formation of irregularly shaped (serpiginous) lesions involving two layers of the eye surface (the retinal pigment epithelium and the choriocapillaris). It is a rare c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b8c3279c2dea630b7d2fe4ebfba7694
https://doi.org/10.18203/2319-2003.ijbcp20203154
https://doi.org/10.18203/2319-2003.ijbcp20203154
Publikováno v:
British Journal of Pharmaceutical Research. 6:166-173
Background: Cardiovascular diseases are one of the leading causes of mortality and morbidity around the globe. Hypertension is directly responsible for 57% of all stroke deaths and 24% of all coronary heart disease deaths in India. As more and more a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea3ca71e93a8895a98580aed9b065d89
https://doi.org/10.9734/bjpr/2015/15520
https://doi.org/10.9734/bjpr/2015/15520
Autor:
Abhijeet D Joshi, Vallish Bn, Shyamal R Sinha, Raj Kishore Mahato, Avinash V Turankar, Sadiq B Patel
Publikováno v:
Journal of Young Pharmacists. 6:32-36
Background: Presently available anti-seizure drugs cannot control seizures in 20-40% epilepsy patients who develop refractory epilepsy. None of the currently available anti-seizure drugs target hypersynchronization of epileptogenic impulses. Process
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87b5dd6dc8654a423937eb73139e154
https://doi.org/10.5530/jyp.2014.3.6
https://doi.org/10.5530/jyp.2014.3.6